Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus

Summary

This is a multicenter, open-label extension study designed to examine the long-term safety of pramlintide treatment in subjects with type 1 diabetes who have successfully completed treatment in the parent study 137-150.

Timeline

Start

2002-11

Primary completion

2005-06

Completion

2005-06

Publications

• Kovatchev BP, Crean J, McCall A. Pramlintide reduces the risks associated with glucose variability in type 1 diabetes. Diabetes Technol Ther. 2008 Oct;10(5):391-6. doi: 10.1089/dia.2007.0295.

Drugs

Indications